Clinical Trials
791 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT03388619 2026-05-27
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04846920 2026-05-22
MK-6482-018
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01823562 2026-05-20
Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00911118 2026-05-18
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01334073 2026-05-14
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT02206334 2026-05-07
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
Phase 1 Completed
NCT03123978 2026-05-06
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
University of California, Davis
Phase 1 Completed
NCT05375539 2026-05-06
AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Milton S. Hershey Medical Center
Phase 1 Completed
NCT03218826 2026-04-29
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT05177042 2026-04-28
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Arvinas Inc.
Phase 1 Completed
NCT06104449 2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02913196 2026-04-20
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT05022849 2026-04-17
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Janssen Research & Development, LLC
Phase 1 Completed
NCT01352962 2026-04-14
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT03674814 2026-03-31
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Completed
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06108479 2026-03-18
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1 Completed
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT06894771 2026-03-16
MK-4700-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01104350 2026-03-05
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
NCT04610671 2026-02-27
Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02776436 2026-02-17
REDEX
Leiden University Medical Center
Phase 1 Completed
NCT04397276 2026-02-17
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Phase 1 Completed
NCT03995888 2026-02-12
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Phase 1 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02989064 2026-02-04
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Phase 1 Completed
NCT05360680 2026-01-22
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cue Biopharma
Phase 1 Completed
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT06840548 2026-01-13
OncoCAIX
Philogen S.p.A.
Phase 1 Completed
NCT06840535 2026-01-06
OncoACP-3
Philogen S.p.A.
Phase 1 Completed
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT05162573 2025-12-10
PROQURE-1
The Netherlands Cancer Institute
Phase 1 Completed
NCT03575013 2025-12-03
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
Phase 1 Completed
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT04169711 2025-10-09
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals
Phase 1 Completed
NCT03253744 2025-10-08
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT01218854 2025-09-22
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04521361 2025-09-19
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Bayer
Phase 1 Completed
NCT04344795 2025-09-12
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Tempest Therapeutics
Phase 1 Completed
NCT04702737 2025-09-12
DeLLpro-300
Amgen
Phase 1 Completed
NCT07014488 2025-09-10
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05114668 2025-09-02
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
Phase 1 Completed
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed